



## Summary of CV

This section describes briefly a summary of your career in science, academic and research; the main scientific and technological achievements and goals in your line of research in the medium -and long- term. It also includes other important aspects or peculiarities.

Dr. Joan Bladé, the principal investigators of the present Project, is the Head of the Amyloidosis and Myeloma Unit at Hospital Clinic in Barcelona. He has been the chairman of the PETHEMA myeloma trials since 1985, Secretary of the Myeloma group (1993-2001), Founder of the PETHEMA Foundation in 1995 and its current vice-president and Secretary of the International Myeloma Society (2011-2015). As secretary of the IMS he established the new rules for the Waldenström's Award election and he created the Bart Barlogie Young Investigator Award, given for the first time at the IMW in Rome 2015. He obtained a number of competitive research grants including RETICs (2003 to 2016) and raised funding for PETHEMA investigator initiative trials for over 9 million euros. He has focussed his research on MM and AL amyloidosis being his main achievements: 1) development of the EBMT response criteria frequently required by regulatory agencies such as FDA and EMEA for new drug approval, recognition of the importance of CR achievement after ASCT and the frequency and effect of oligoclonal bands in the definition of stringent CR, 2) recognition for the first time of two clinically and biologically different types of MGUS and SMM (i.e., evolving vs. non-evolving), 3) first group to recognize the lack of efficacy of thalidomide as well as the efficacy of bortezomib in the extramedullary myeloma involvement, 4) demonstration of the superiority of ASCT over combination chemotherapy, and 5) identification of the bortezomib, thalidomide and dexamethasone (VTD) combination as the best pre-transplant anti-myeloma regimen (approved by the EMEA in 2014).

Dr. Bladé has published 267 scientific papers (57 as first author and 43 as senior author) in international peer reviewed journals including 44 in Blood, 32 in Br J Haematol, 22 in Haematologica, 19 in Leukemia, 17 in J Clin Oncol, 6 in Arch Intern Med or 5 in the N Engl J Med. The total IF is 2,152 with a median per publication of 8.1. His H-index is 71 with 21.547 citations in 10.170 articles being the average citation per publication of 28. He was recognized in as one of the 1% more cited researchers during the period 2002-2012 by the Thompson and Reuters agency 2014. All the above resulted in a number of recognitions such as the Robert Kyle Lifetime Achievement Award 2010 by the International Myeloma Foundation, the annual Spanish Society of Hematology Antonio Raichs Award 2011 or the Joseph Michaeli Research Award for Contributions to Myeloma Research, New York 2012.